


High-Throughput Screening at The University of Chicago Cellular Screening Center

Sam Bettis
Technical Director
sbettis@bsd.uchicago.edu

High-Throughput Screening at The University of Chicago

- ❑ Cellular Screening Center (CSC):
Opened in January of 2007
 - ❑ In six years the CSC has run over 70 high-throughput screens
- ❑ Perform small molecule and siRNA screens for investigators throughout Chicago
 - ❑ Over 160,000 small molecules
 - ❑ Whole genome siRNA library (ThermoFisher Dharmacon)
- ❑ 900 ft² of cleanroom lab space: All screening areas are Class 100
- ❑ 8 liquid handlers and 3 readers (two high-content) with a multi-axis arm on a 3m rail



Available Chemical Libraries at The University of Chicago



Cellular Screening Center

<http://igsb.org/services/csc/>

Sam Bettis, Technical Director

UCCCC Drug Discovery Core

Geoffrey Greene, Director

Compound Collections: Automated storage and retrieval for ~200,000 compounds; diverse scaffolds that cover as much chemical space as possible.

MicroSource Spectrum library: ~2,000 cpds - 50% (800 USP/USAN + 200 INN & BAN & JAN) known drugs, 30% (580) natural products, 20% (420) other bioactive compounds.

<http://www.msdiscovery.com/spectrum.html>

Prestwick Chemical Library: 1200 FDA approved drugs.

<http://www.prestwickchemical.com/index.php?pa=26>

The Prestwick Chemical Library® contains 1200 small molecules, 100% FDA approved drugs, thus it presents the greatest possible degree of “drug-likeness”. The active compounds were selected for their high chemical and pharmacological diversity as well as for their known bioavailability and safety in humans. The Prestwick Chemical Library® contains a limited number of highly diverse drug molecules for which bioavailability and toxicity studies have already been performed and which have proven usefulness in humans.

Available Chemical Libraries at The University of Chicago

Chembridge Express-Pick collection: 130,000 cpds from the MicroFormat library. Stock compounds are selected using novelty, diversity, drug-like property analysis, and medicinal chemistry expertise. In addition, 50,000 compounds available as pooled plates - 8 cpds/well. These cpds come from the 130,000 cpd collection.

<http://igsb.org/services/csc/>

Chembridge DIVERSet Collection: 50,000 cpds

Extensive pharmacophore coverage for primary screening. Stringent drug-like and desirable chemical group filters coupled with a 3D conformer analysis are used in selecting a premium set of 50,000 drug-like compounds with maximum pharmacophore coverage and chemical diversity


CTCMLD collection: ~10,000 diverse cpds

Chicago Tri-Institutional Center for Chemical Methods and Library Development




Sergey Kozmin, Director

Karl Scheidt, Project 1 Leader


<http://ctcml.d.uchicago.edu>




Diversity Analysis Using Principal Moments of Inertia (PMI) of CTCMLD Compounds




Yield: 18.0 mg (72%);
 Purity (ELSD): 100%
 MW: 589.7
 Average ClogP: 2.41






Yield: 23.0 mg (87%);
 Purity (ELSD): 100%
 MW: 565.6
 Average ClogP: 1.09



Yield: 21.9 mg (72%);
 Purity (ELSD): 100%
 Mw: 641.3
 Average ClogP: 3.29






Yield: 19.7 mg (86%);
 Purity (ELSD): 100%
 MW: 589.7
 Average ClogP: 3.39




Unique Capabilities at The University of Chicago

- ❑ Unique chemical libraries
- ❑ Flexible screening platform for enzymatic and cell-based screening
- ❑ Over 350 cell lines available in-house for immediate screening
- ❑ Class 100 clean room BSL2+ environment for sterility and reproducibility



- ❑ Extensive screening experience in both compound screening and siRNA screening
 - ❑ Staff with experience in both industry and academia
- ❑ Work completed on unique targets and orphan diseases that are ignored by biotech/pharma
- ❑ Two high-content readers are integrated for 24/7 reads with cutting-edge analysis tools and reliable data storage



- ❑ We are discovering novel entities to further drug discovery in a wide variety of assays and disease areas
- ❑ We possess unique libraries, technology, and infrastructure to provide reliable and robust data for investigators
- ❑ We provide decades of experience in small molecule and siRNA screening
- ❑ Our setup is flexible and efficient which allows users to complete large screens in a reasonable time frame at a lower cost